DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20191773

Aggressive mycosis fungoides/sézary syndrome in Nigeria: case report and literature review

Oreoluwa Arowojolu, Oluwasegun Afolaranmi, Mutiu Jimoh

Abstract


Mycosis fungoides and its variant, sézary syndrome are rare neoplastic conditions which are part of a larger group of lymphomas that primarily affect the skin known as cutaneous T-cell lymphomas. We report a case of fatal aggressive mycosis fungoides/sézary syndrome in a 55-year old Nigerian man who initially developed pruritic hyperpigmented spots on his skin which progressed over the course of 5 years to widespread scaly mixed hyperpigmented and hypopigmented plaques and nodules with features of organ involvement despite being managed with Psoralen and ultraviolet A radiation (PUVA), total skin electron-beam (TSEB), local electron-beam radiation, bexarotene, and oral prednisolone and chlorambucil (Winklemann regimen). In the process, we highlight the rarity of the condition, its ease of misdiagnosis and its predilection for people of Sub-Saharan decent.


Keywords


Mycosis fungoides, Sézary syndrome, Cutaneous T-cell lymphomas, Nigeria, Africa

Full Text:

PDF

References


Alibert J. Description Des Maladies de La Peau Observées à l’Hôpital Saint-Louis et Exposition Des Meilleures Méthodes Suivies Pour Leur Traitement. Paris, Barrois l’aîné et Fils. Paris; 1806.

Lutzner M, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med. 1975;83(4):534-52.

Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer. 1999;85(1):208-12.

Jenni D, Karpova MB, Seifert B, Golling P, Cozzio A, Kempf W, et al. Primary cutaneous lymphoma: Two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre. Br J Dermatol. 2011;164(5):1071-7.

Alsaleh QA, Nanda A, Al-Ajmi H, Al-Sabah H, Elkashlan M, Al-Shemmari S, et al. Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006. Int J Dermatol. 2010;49(12):1393-8.

Lippincott, Williams, Wilkins. Cutaneous Lymphomas and Leukemias. In: Lever’s Histopathology of The Skin. ; 2005: 927-978.

van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136(4):504-10.

Cuneo A, Castoldi G. Leukaemia Section Mini Review Atlas of Genetics and Cytogenetics in Oncology and Haematology Mycosis fungoides/Sezary’s syndrome Clinics and pathology Phenotype/cell stem origin. Atlas Genet Cytogenet Oncol Haematol. 2005;9(3):1.

Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol. 2012;51(10):1195-8.

Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47:1056.

Morales-Suárez-Varela MM, Olsen J, Johansen P. Occupational risk factors for mycosis fungoides: a European multicenter case-control study. J Occup Environ Med. 2004;46(3):205-11.

Girardi M, Heald PW, Wilson LD. The Pathogenesis of Mycosis Fungoides. N Engl J Med. 2004;350(19):1978-88.

Zendri E, Pilotti E, Perez M, Turci M, Pinelli S, Ronzi P, et al. The HTLV tax-like sequences in cutaneous T-cell lymphoma patients. J Invest Dermatol. 2008;128(2):489-92.

Courgnaud V, Duthanh A, Guillot B, Sitbon M, Dereure O. Absence of HTLV-Related Sequences in Skin Lesions and Peripheral Blood of Cutaneous T-Cell Lymphomas. J Invest Dermatol. 2009;129(10):2520-2.

Ballanger F, Bressollette C, Volteau C, Planche L, Dreno B. Cytomegalovirus: its potential role in the development of cutaneous T-cell lymphoma. Exp Dermatol. 2009;18(6):574-6.

Vidulich KA, Rady PL, He Q, Tyring SK, Duvic M. Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. Int J Dermatol. 2009;48(6):598-602.

Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-22.

PDQ Adult Treatment Editorial Board PATE. Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®): Health Professional Version. National Cancer Institute (US); 2002.

Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999;89(8):1240-4..

Cerroni L, Gatter K, Kerl HE. Mycosis Fungoides. In: Skin Lymphoma. The Illustrated Guide. 3rd ed. Oxford, UK: Wiley/Blackwell; 2009: 11-56.

Campbell OB, George AO, Shokunbi WA, Akang EE, Aghadiuno PU. Problems in the management of mycosis fungoides in Nigeria. Trop Geogr Med. 1991;43(3):317-22.

Trautinger F, Eder J, Assaf C. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/SEzary syndrome - Update 2017. Eur J Cancer. 2017;77:57-74.

Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol. 1999;26(3):276-89.

Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766-73.

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: Validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-9.